What Гинестрил Treats: Main Uses and Benefits

Гинестрил is commonly used in situations involving certain distressing symptoms, offering targeted symptomatic relief and supportive relief. It is utilized to assist with concerns related to both reproductive health and systemic imbalances.

---

It is relevant in clinical settings marked by increased discomfort or tension, commonly used across conditions presenting with acute episodes such as uterine leiomyomata (fibroids) and conditions involving systemic imbalance like severe hyperglycemia associated with endogenous Cushing Syndrome. In gynecological settings, it helps to manage symptom clusters that may become intense or disruptive, such as heavy menstrual bleeding and pelvic pressure. In endocrine settings, it is relevant for managing symptoms related to systemic imbalance, where glucose intolerance and high blood sugar create noticeable physiological strain.

“It is applied in clinical settings that involve acute or unstable symptom patterns, offering support that helps ease the overall symptom burden.”

This provides supportive relief that assists with maintaining functional stability during symptomatic periods and helps patients cope more steadily with challenging symptoms.

---

Quick Fact: Support for Progesterone-Driven Symptoms

Гинестрил is commonly used to help with conditions characterized by periods of heightened symptoms, such as uterine fibroids, providing support to ease discomfort and supports general well-being during symptomatic phases.

Regulatory References

1. Mifepristone - StatPearls - NCBI Bookshelf

Гинестрил (Ginestril) is a medication containing the active ingredient mifepristone, a synthetic steroid that acts as an antiprogestogen. In certain formulations and dosages, it is primarily used in gynecology.

Who Can Use Гинестрил?

The most common authorized use for mifepristone-containing products in gynecology is the treatment of uterine leiomyoma (fibroids) in women of reproductive age, particularly when the size of the fibroids corresponds to a maximum of 12 weeks of pregnancy. Its mechanism involves blocking progesterone receptors, which can help stop the growth of the tumor and reduce the size of the uterus and myomatous nodes.

Who Cannot Use Гинестрил?

Гинестрил is contraindicated in a number of conditions due to the risk of serious adverse effects. Patients should not use this medication if they have:

• Pregnancy or Lactation (breastfeeding).
• Hypersensitivity (allergy) to mifepristone.
• Adrenal insufficiency or are on long-term corticosteroid therapy.
• Acute or chronic renal or hepatic failure.
• Porphyria, severe anemia, or hemostasis disorders (including those treated with anticoagulants).
• Inflammatory diseases of the female genital organs.
• Submucosal location of myomatous nodes.
• Uterine leiomyoma size greater than a 12-week pregnancy equivalent.
• Tumors of the ovaries and/or endometrial hyperplasia.
• Severe extragenital pathology (pre-existing serious non-reproductive health conditions).

Interactions with other medicines and products

Mifepristone (Гинестрил) is associated with several clinically significant interactions, primarily due to its effects on the liver's CYP3A4 enzyme system and its own activity as a CYP inhibitor. The official regulatory labeling documents these interactions, leading to specific use restrictions.

Metabolic (Pharmacokinetic) Interactions

Mifepristone is metabolized by CYP3A4, and it is also a potent inhibitor of this enzyme, affecting the metabolism of numerous other drugs. It also weakly inhibits CYP2C8, CYP2C9, and the P-glycoprotein (P-gp) transporter.

Interaction Type	Examples of Affected Substances	Regulatory Requirement
Exposure Reduction (Induction)	Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort, Phenytoin)	Concurrent use must be avoided due to risk of lower Mifepristone effectiveness.
Exposure Increase (Inhibition)	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Grapefruit Juice)	Use with caution due to increased Mifepristone exposure; dosage adjustments may be required.

Pharmacodynamic and Contraindicated Interactions

Certain combinations are contraindicated or require extreme caution due to additive risks, regardless of metabolic effects. The label prohibits co-administration with drugs primarily metabolized by CYP3A4 that possess a narrow therapeutic index (e.g., Simvastatin, Cyclosporine) for certain Mifepristone uses. Furthermore, concurrent use with anticoagulant therapy is contraindicated for the pregnancy termination indication due to the documented increase in the risk of severe or prolonged bleeding.

The function of Гинестрил (Mifepristone) is defined by its specific action within key hormonal and physiological regulatory domains, leading to a cascade of effects that modulate uterine processes.

Blocking Progesterone Signaling at the Receptor Level

The drug's primary action is the competitive antagonism of the Progesterone Receptor (PR). This molecular blockade prevents the endogenous hormone, progesterone, from activating the receptor complex, thereby suppressing the necessary gene transcription required for maintaining the uterine lining. This ultimately triggers the structural breakdown and shedding of progesterone-dependent tissue.

Enhancing Uterine Contraction Sensitivity

A key downstream effect of the PR antagonism is the modulation of myometrial tone. By neutralizing progesterone's inhibitory influence on the uterine muscle, the drug increases the tissue's responsiveness to prostaglandins and other natural contractile agents. This functional change generates coordinated uterine contractions, which are a consequence of the mechanism.

Inducing Connective Tissue Remodeling

The mechanism extends to the structural integrity of the reproductive tract by promoting the enzymatic degradation of collagen. This process, mediated by the induction of Matrix Metalloproteinases (MMPs), results in the softening and ripening of the cervix, which is a resulting physiological component.

How to Use Гинестрил (Mifepristone): Official Administration Guidelines

The administration of Mifepristone (the active ingredient in Гинестрил) is highly prescriptive and depends on the condition being addressed, following established protocols. The official routes and methods are outlined below, focusing strictly on administration and dosing descriptions as defined in the product labeling.

---

Official Dosing and Administration

Feature	General Guideline
Route of Administration	Oral Tablet.
Formulation Requirement	The tablets are to be swallowed whole and should not be split, crushed, or chewed.
Timing in Relation to Meals	For continuous, daily therapy (e.g., in Cushing Syndrome), the medication is taken with food.

---

Indication-Specific Use Patterns

The frequency and dose vary and are categorized into short-course procedures and long-term continuous therapy:

• Long-term, Continuous Use (e.g., Cushing Syndrome): The starting dose is typically 300 mg once daily. The dose may be increased in 300 mg increments every 2–4 weeks, up to a maximum of 1200 mg per day. This is a sustained regimen involving a period of gradual dose titration.
• Short-course, Single-Dose Use (e.g., Medical Termination): A single 200 mg dose of mifepristone is administered orally. This is followed by a co-administered medication 24 to 48 hours later, and a follow-up assessment is conducted 7 to 14 days after the mifepristone dose.

---

Population-Based Adjustments and Special Conditions

For continuous therapy, dose limits are set for patients with certain pre-existing conditions. For instance, the maximum daily dose is restricted to 600 mg for individuals with mild to moderate hepatic or renal impairment. Additionally, the dispensing for specific uses is subject to restricted distribution programs, and any intrauterine device must be removed prior to starting treatment.

Research Evidence / Overview of Studies

---

Core Mechanism and Phase 1 Trials

Initial research focused on how the drug affects the body, as part of the evaluation of the inflammatory response. This initial research assessed initial human response across various doses in healthy volunteers.

Phase 1 studies assessed initial human response across various doses, with reported findings focused on common adverse events. No serious adverse events were reported during these early trials.

---

Research on Autoimmune Conditions

The primary research focus has been the potential application in rheumatoid arthritis and psoriatic arthritis. Small-scale trials evaluated joint function and stiffness. Outcomes included changes in function and stiffness scores.

Phase 2 studies reported observations related to disease activity over 6 months in a cohort of participants with moderate-to-severe disease. Research has explored its use in early-stage autoimmune conditions. A variety of dosing schedules were examined to identify well-tolerated administration routes.

One study examined outcomes in patients who did not respond to standard treatments. This research assessed secondary endpoints, including quality of life metrics and patient-reported pain levels.

---

Combination Research

Research explored the co-administration with other therapies, evaluating patient outcomes.

One open-label study evaluated the drug alongside a common non-steroidal anti-inflammatory drug (NSAID) to observe tolerability. Another study protocol specified administration at the same time each day to monitor the consistency of measured drug levels.

The trials included participants with mild liver impairment. Participants with moderate impairment were excluded from the study.

Key Studies & References

1. Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment (Systematic Review)

Common questions about Гинестрил (FAQ)

---

Q: What is the specific maximum dose for continuous use (not for termination)?

According to official regulatory labeling for continuous treatment regimens, the dose is started lower and may be gradually increased. Official product information indicates that the maximum daily dosage that may be reached during dose adjustments is 1200 mg.

---

Q: What is the name of the chemical class that this drug belongs to?

Гинестрил, which contains mifepristone, is classified primarily as a progestin antagonist, sometimes called an antiprogestational steroid. This means it works by blocking the effects of the hormone progesterone. It also has a secondary classification as an antiglucocorticoid, as it can block cortisol receptors.

---

Q: Can this medication cause permanent side effects, like changes to the voice?

Official product information notes that certain androgenic effects, which are related to male hormones, may be persistent or irreversible. These effects are reported to include excessive hair growth (hirsutism) and a deepening of the voice.

---

Q: What is the process for disposing of expired or unused Гинестрил?

Regulatory guidelines advise against saving outdated or unneeded medicine. To ensure proper public and environmental safety, it is recommended to consult a healthcare professional or pharmacist. They can provide guidance on disposal procedures.

---

Q: What should I do if I miss a dose of Гинестрил?

Product labeling often states that if a dose is missed, it should generally be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped. The label also advises against taking a double dose to compensate for a missed one.

Storage and Disposal Requirements for Mifepristone (Гинестрил)

The storage and disposal instructions for Mifepristone tablets are strictly governed by regulatory labeling to maintain product stability and ensure public safety.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Do not store above 30 C (or 25 C, depending on the formulation).
Protection	Store in the original package in order to protect from light.
Child Safety	Must be kept out of the sight and reach of children.

Disposal

Disposal of any unused or expired product must be done in accordance with local requirements, such as returning it to a pharmacy. The medicine should not be disposed of via wastewater or household waste to prevent environmental contamination.